Answers are grounded in this paper and cite their sources.
The discovery of 4 distinct molecular endometrial cancer subgroups by The Cancer Genome Atlas has fundamentally changed the way we look at endometrial carcinoma today. The proven robustness of surrogate markers in a diagnostic algorithm endorsed by the World Health Organization classification of female genital tumors 2020 has opened the gates for worldwide implementation. This advance delivers a reproducible classification system with improved prognostication and a biological basis for future targeted treatments. Although we all embrace this exciting development, we now struggle how to position the traditional histology-based classification (histotype/International Federation of Gynecology and Obstetrics grade). The author discusses the strengths, weaknesses, opportunities, and threats and deliberates on how we could bring the best of both worlds together.
No takes yet. Share an insight, caveat, or question.
Tjalling Bosse (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: